

Document No.:	Edition No.:	Effective Date:	Page:
HRP-010	001	18 Jan 2019	Page 1 of 10

### 1. PURPOSE

1.1. This policy establishes the Carilion Clinic's Human Research Protection Program (HRPP) and its commitment to protect the rights and welfare of human subjects.

### 2. GUIDELINE

- 2.1. Scope
  - 2.1.1. The HRPP applies to:
    - 2.1.1.1. All <Human Research> which engages Carilion Clinic as defined by "WORKSHEET: Engagement (HRP-422)."
    - 2.1.1.2. All <Human Research> submitted to the IRB for review.
  - 2.1.2. <Human Research> may not commence until IRB approved.
  - 2.1.3. Activities that are not <Human Research> do not require IRB review unless there is uncertainty whether the activity is <Human Research>.
  - 2.1.4. Direct questions about whether an activity (such as classroom research, quality improvement, case reports, program evaluation, or surveillance activities) represents <Human Research> to the IRB. The IRB provides written determinations in response to written requests.
  - 2.1.5. Direct questions about whether Carilion Clinic is engaged in <Human Research> to the IRB. The IRB provides written determinations in response to written requests.
  - 2.1.6. After a study is completed, Carilion Clinic does not consider the return of results to former subjects to be <Human Research>.
- 2.2. Ethical Principles
  - 2.2.1. Carilion Clinic follows the ethical principles described in the report "Ethical Principles and Guidelines for the Protection of Human Subjects of Research" also known as "The Belmont Report." (see Reference 1)
  - 2.2.2. Carilion Clinic applies its ethical principles to all <Human Research> regardless of support or geographic location.
    - 2.2.2.1. Policies and procedures applied to research conducted domestically are applied to international research.
  - 2.2.3. The following categories of individuals are expected to abide by these ethical requirements:
    - 2.2.3.1. Investigators (whether professional or student)
    - 2.2.3.2. Research staff
    - 2.2.3.3. IRB members, IRB chairs, and IRB vice-chairs
    - 2.2.3.4. HRPP staff members
    - 2.2.3.5. Carilion Clinical Institutional Official
    - 2.2.3.6. Employees and agents
  - 2.2.4. Clinical trials should be conducted in accordance with the ethical principles in Reference 1 that have their origin in the Declaration of Helsinki and are consistent with good clinical practice and the applicable regulatory requirements.
- 2.3. Review and Oversight Requirements
  - 2.3.1. The Carilion Clinic applies FDA regulations, the <Original Rule>, the <Revised Rule>, and 45 CFR §46 Subparts B, C, and D as described in the Tables in the References section.



LINIC	Document No.:	Edition No.:	Effective Date:	Page:
view Board	HRP-010	001	18 Jan 2019dd	Page 2 of 10
			MMM	0

2.3.2. Carilion Clinic applies the following requirements to non-exempt <Human Research as Defined by HHS> that is conducted, supported, or otherwise subject to regulation by the following federal departments or agencies:

- 2.3.2.1. DOD: 10 USC 980, DOD Instruction 3216.02, OPNAVINST 5300.8B, and SECNAVINST 3900.39D
- 2.3.2.2. DOE: DOE Order 443.1A and used "Checklist for IRBs to Use in Verifying That HS Research Protocols Are in Compliance with the Department of Energy (DOE) Requirements".
- 2.3.2.3. DOJ: 28 CFR §22 and 28 CFR §512.
- 2.3.2.4. ED: 34 CFR §97 Subpart D (equivalent to 45 CFR §46 Subpart D), 34 CFR §98, 34 CFR §99, and 34 CFR §356.
- 2.3.2.5. EPA: 40 CFR §26 and EPA Order 1000.17 Change A1.
- 2.3.3. Carilion Clinic applies 45 CFR §46 Subparts B, C, and D to the extent required by OHRP<sup>1</sup> to all non-exempt <Human Research as Defined by HHS>.
- 2.3.4. Carilion Clinic commits to apply the "International Conference on Harmonisation Good Clinical Practice E6." (ICH-GCP) to <Human Research> evaluating the safety or effectiveness of a drug or biologic.
- 2.3.5. Carilion Clinic applies all policies and procedures applied to research conducted domestically to research conducted in other countries, including:
  - 2.3.5.1. Confirming the qualifications of investigators for conducting the research
  - 2.3.5.2. Conducting initial review, continuing review, and review of modifications to previously approved research
  - 2.3.5.3. Post-approval monitoring
  - 2.3.5.4. Handling of complaints, non-compliance, and unanticipated problems involving risks to subjects or others
  - 2.3.5.5. Consent process and other language issues
  - 2.3.5.6. Ensuring all necessary approvals are met
  - 2.3.5.7. Coordination and communication with local IRBs
  - 2.3.5.8. Encompassing activities that are "research involving human participants" as defined by local laws.
- 2.3.6. Carilion Clinic prohibits payments to professionals in exchange for referrals of potential subjects ("finder's fees").
- 2.3.7. This IRB reviews payments designed to accelerate recruitment that are tied to the rate or timing of enrollment ("bonus payments") and does not allow them unless the possibility of coercion and undue influence is minimized.
- 2.4. Components of the HRPP
  - 2.4.1. Carilion Clinical Institutional Official
    - 2.4.1.1. Carilion Clinical Institutional Official is the leader of the HRPP.
    - 2.4.1.2. The Carilion Clinical Institutional Official is authorized to:
      - 2.4.1.2.1. Allocate HRPP resources
      - 2.4.1.2.2. Appoint and remove IRB members, IRB chairs, and IRB vice-chairs
      - 2.4.1.2.3. Bind HRPP policies on the Carilion Clinic
      - 2.4.1.2.4. Determine what IRBs the Carilion Clinic will rely upon
      - 2.4.1.2.5. Disapprove, suspend, or terminate <Human Research>

<sup>&</sup>lt;sup>1</sup> OHRP has indicated that for research not conducted, supported, or otherwise subject to regulation by a federal department or agency, OHRP will not review reports (e.g., unanticipated problems, non-compliance, suspensions, terminations), will not provide secretarial review of not otherwise approvable research under Subparts B and D, and will not certify prisoner research under Subpart C.



RILIONCLINIC		Document No.:	Edition No.:	Effective Date:	Page:
itutional Review Boar	d	HRP-010	001	18 Jan 2019dd	Page 3 of 10
2	2.4.1.2 2.4.1.2 2.4.1.2 2.4.1.2 2.4.1.2 2.4.1.2 2.4.1.2	2.7. Limit or c 2.8. Determin Noncomp <unantici Others&gt;, <termina 2.9. Act again or <conti 2.10. Sign IRB</conti </termina </unantici 	fire HRPP staff m ondition privileges e that information pliance>, <continu ipated Problem In a <suspension of<br="">ation of IRB Appro st employees rela nuing Noncomplia authorization agr or terminate <hu< th=""><th>embers s to conduct <hui represents <ser uing Noncompliar volving Risks to S f IRB Approval&gt;, val&gt; ated to <serious i<br="">ance&gt; eements</serious></ser </hui </th><th>ious nce&gt;, an Subjects or or a</th></hu<></suspension></continu 	embers s to conduct <hui represents <ser uing Noncompliar volving Risks to S f IRB Approval&gt;, val&gt; ated to <serious i<br="">ance&gt; eements</serious></ser </hui 	ious nce>, an Subjects or or a
	Carilior 2.4.1.3 2.4.1.3 2.4.1.3 2.4.1.3 2.4.1.3 2.4.1.3 2.4.1.3 2.4.1.3 2.4.1.3 2.4.1.3 2.4.1.3	<ul> <li>B.1. Oversee</li> <li>B.2. Ensure the are appropriate approprint appropriate approprise appropriate approprise approprise appropriate appropr</li></ul>	tional Official is re- the HRPP ne independence opriately handled nat complaints and opriately handled nat the HRPP has propriate for the ver- a culture of complete and timely manner a culture of complete and correct aller on the <human f<br="">te and correct system Ily review HRPP p nd sign federal as</human>	of the review prod d allegations rega sufficient resourd olume and types hat reviews are ac er bliance with HRPI egations and findi Research> review stemic problems r policies and proc	arding the HRPP ces, including of <human ccomplished in a P requirements ngs of undue y process related to the edures</human 
2.4.2.1. / ( 2.4.2.2. /	All emp Carilior	n Clinical Institu ployees and age 2.1. Be aware 2.2. Be aware 2.3. Consult th	Carilion Clinic: ents of the Carilion tional Official for I ents of the Carilion of this policy. of the definition of he IRB when ther <human researd<="" th=""><th>HRPP issues. n Clinic are respo of <human resea<br="">e is uncertainty a</human></th><td>onsible to: arch&gt;.</td></human>	HRPP issues. n Clinic are respo of <human resea<br="">e is uncertainty a</human>	onsible to: arch>.
	- 4		<ruman kesear<="" th=""><th>Ch&gt;.</th><td>Deserved</td></ruman>	Ch>.	Deserved

- 2.4.2.2.4. Not conduct <Human Research> without IRB approval.
- 2.4.2.2.5. Report allegations of undue influence related to the HRPP.
- 2.4.2.2.6. Report <Allegations of Noncompliance> or <Findings of Noncompliance>.
- 2.4.3. IRB members and HRPP staff members
  - 2.4.3.1. IRB members, IRB chairs, IRB vice-chairs, and HRPP staff members are responsible to:
    - 2.4.3.1.1. Follow HRPP policies and procedures
    - 2.4.3.1.2. Undergo initial training, including training on specific federal agency requirements (e.g., DOD) when such research is reviewed
    - 2.4.3.1.3. Participate in continuing education activities at least annually, including training on specific federal agency requirements (e.g., DOD) when such research is reviewed
    - 2.4.3.1.4. Respond to contacts from participants or others



2.4.4.

## **GUIDELINE: Human Research Protection** Program

CLINIC			yran			-
			nent No.:	Edition No.:	Effective Date:	Page:
eview Boa	rd	HF	RP-010	001	18 Jan 2019dd	Page 4 of 10
	2.4.3. 2.4.3.	1.6.	the IRB w Ensure re requireme		cipants or others the IRB's written I to an external IF	procedures RB meets local
	2.4.3.		approvals	search approved before being cor	nducted	
2.4.3.2. 2.4.3.3.	IRB m	embe	rs and HRI	ed to suspend or PP staff members ficial for HRPP is	s ultimately repor	
IRB						
2.4.4.1. 2.4.4.2.	Autho	rizatio		v upon the IRB of ent for IRB review rity:		
	2.4.4.	2.1.	disapprov	ve, require modifi re all <human re<br="">d by Carilion Clini</human>	search>.activities	
	2.4.4.	2.2.	not being requireme	nd or terminate a conducted in acc ents or that had b arm to participant	cordance with HR een associated w	PP
	2.4.4.		To observ	ve, or have a third and the conduct o	l party observe, t f the <human re<="" td=""><td>esearch&gt;.</td></human>	esearch>.
	2.4.4. 2.4.4.			e whether an acti e whether Carilion >		
	2.4.4.	2.6.	Research	whether financia > and the manag an Research>.		
2.4.4.3.	Carilio appro		ic cannot a	approve <human< td=""><td>Research&gt; that t</td><td>he IRB has not</td></human<>	Research> that t	he IRB has not
2.4.4.4.	Exterr Carilic	nal org on Clin on an	ic's IRB to	relying on Carilic do the following RB the Carilion Cl	and when the Ca	rilion Clinic
	2.4.4. 2.4.4.			e whether an acti e whether <huma clinic</huma 		
	2.4.4.	4.3.	Determine	e which persons a uman Research>		ngaged (agents)
	2.4.4.	4.4.	Assure al	I IRB members, I accordance with	RB Chairs and Vi	
	2.4.4.	4.5.		scientific or schol		
	2.4.4.4	4.6.	For clinica including informatic	al trials, assure IC whether the avail on on an investiga ne clinical trial.	able non-clinical	and clinical
	2.4.4.4	4.7.	Identify a	ny relevant local, ents related to <h< td=""><td></td><td></td></h<>		

elated to <Human Research>, and apply AAHRPP criteria to international research. 2.4.4.4.8. Make contact information for the IRB available to current and former subjects.



Effective Date:

Page:

Edition No.:

Document No.:

ard	HF	RP-010	001	18 Jan 2019dd	Page 5 of 10		
2.4.4.4	4.9.			contact someone			
				ons, concerns, cor	mplaints, or		
			phts, or to offer in				
2.4.4.4	4.10.			owledge of comm			
		is reviewe	•	nd meetings whe	re such research		
2.4.4.4	1 1 1			nanticipated Probl	lems Involving		
2.4.4.	+.    .			s>, <noncomplia< td=""><td></td></noncomplia<>			
				ntinuing Noncom			
				to conduct an au			
2.4.4.4	4.12.			Illegation of nonco			
				each incident of n			
			continuing, inclu	uding when neces	sary to conduct		
		an audit.					
2.4.4.4	4.13.			roblems Involving			
				ncompliance>, <s ntinuing Noncom</s 			
				val> and <termi< td=""><td></td></termi<>			
		Approval>					
2.4.4.4	4.14.			rate with the Cari	lion Clinic to		
				roblems Involving			
				ncompliance>, <Š			
				ntinuing Noncom			
				oval> and <termi< td=""><td>nation of IRB</td></termi<>	nation of IRB		
0.4.4		Approval>		antisis at al Deala			
2.4.4.4	4.15.	Notify the FDA of any <unanticipated involving<br="" problems="">Risks to Subjects or Others&gt;, <serious noncompliance=""></serious></unanticipated>					
Risks to s and <cor< td=""><td colspan="5">itinuing Noncompliance&gt;, <senous noncompliance=""></senous></td></cor<>			itinuing Noncompliance>, <senous noncompliance=""></senous>				
		Approval> and <termination approval.<="" irb="" of="" td=""></termination>					
2.4.4.4	4.16.			on Clinic to notify			
				DA of any <unant< td=""><td></td></unant<>			
		Problems Involving Risks to Subjects or Others>, <serious< td=""></serious<>					
		Noncompliance> and <continuing noncompliance="">,</continuing>					
		<suspension approval="" irb="" of=""> and <termination irb<="" of="" td=""></termination></suspension>					
		Approval>					
2.4.4.4	4.17.		interest related t	review to manage	e organizational		
		2.4.4.4.17		rganization is res			
			identify organ	izational conflicts	of interests.		
2.4.4.4	4.18.	Identify ar	nd manage finan	cial conflicts of int	terest of		
		investigat	ors and research	staff and upon re	equest, review		
			porate the relying	g organization's m	nanagement		
2.4.4.4.19.		plan.					
		Evaluate and confirm test articles have appropriate regulatory approval (e.g., IND or IDE, meet exemption					
				ND or IDE, meet	exemption		
		requireme					
		2.4.4.4.19		rganization is res			
				itten policies and			
				ne handling of inv			
				st articles conform	ns to legal and		
			regulatory rec	quirements.			
<b>•</b> • •				· .			

2.4.4.20. Evaluate and permit emergency uses of a test articles and assure uses follow FDA requirements.



# GUIDELINE: Human Research Protection Program Edition No.: Effective Date: Page:


Document No.:		Edition No.:	Effective Date:	Page:			
rd	HF	RP-010	001	18 Jan 2019dd	Page 6 of 10		
2.4.4.4.21. Assure th			at emergency us	es of a test article	es are not		
		considere	d <human resea<="" th=""><th>arch as Defined b</th><th>y HHS&gt; and</th></human>	arch as Defined b	y HHS> and		
				ed from an emerg	jency use for		
			Research as Defi				
2.4.4.	4.22.			esearch staff are			
				ch is DOD-regula			
				ning, and the pos	sibility of DOD		
			of the educationa				
2.4.4.	4.23.			IRB Chairs and			
				applicable IRB S			
~				ch is DOD-regula	ted.		
2.4.4.			DOD research fo		Cartantar		
2.4.4.	4.25.			nine that the invest			
			n to conduct rese on or local ethics	earch in that coun	шу бу		
2.4.4.	1 26				tigator will		
2.4.4.	4.20.			nine that the inves tions, customs, a			
2.4.4.	1 27			as the requiremer			
∠.4.4.	<b>⊣.∠</b> /.			eviewing non-exe			
		DOD rese		eviewing non-exe	shipt classified		
2.4.4.	4 28			na noncompliance	with DOD		
2.7.7.	1.20.	Report serious or continuing noncompliance with DOD research to the DOD human research protection officer.					
2.4.4.	4.29.	Assure all DOE requirements of 10 CFR 745 and DOE					
		Order 443.1.B. are met.					
2.4.4.	4.30.			nts of 28 CFR 22	and 512 are		
		met.					
2.4.4.4.31.		Evaluate	DOJ research to	assure there is a	n adequate		
		research design and it contributes to the advancement of					
		knowledge about corrections.					
2.4.4.	4.32.	Assure all ED requirements of 34 CFR 98, 99 and 356 are					
		met.					
2.4.4.	4.33.			of 40 CFR 26 an			
		1000.17 Change A1 are met, and to flag research that					
		collects data intended to be submitted to EPA as subject to					
-		EPA regulations.					
2.4.4.	4.34.		quivalent protecti	ions for participar	its in non-funded		
	4.0-	research.					
2.4.4.	4.35.			ween any applica			
044	4.00			uired by regulator			
2.4.4.	4.36.			ind research staff	are		
044	4 97	appropriately trained. For international research:					
2.4.4.4.37.		For intern	alional research:				
		2.4.4.4.37	.1. Ensure appro	priate expertise a	and knowledge		
			of the country	(ies) either throu	gh IRB members		
			or consultants				
				ledge of local law			
				ledge of cultural of			
		2.4.4.4.37		ualifications of th			
				staff for conducti	ng research in		
			that country.				
		2.4.4.4.37		I review, continui			
			roviow of mor	difications to prov	Inviely approved		

- 2.4.4.37.5. Conduct initial review, continuing review, and review of modifications to previously approved research.
- 2.4.4.37.6. Conduct post-approval monitoring.



Document No.:	Edition No.:	Effective Date:	Page:
HRP-010	001	18 Jan 2019dd	Page 7 of 10

- 2.4.4.37.7. Handle complaints, noncompliance, and unanticipated problems involving risk to participants or others.
- 2.4.4.37.8. Manage consent process and document and other language issues.
- 2.4.4.37.9. Coordinate and communication with local IRBs when appropriate.
- 2.4.4.38. Should the relying organization terminate reliance on the IRB, the IRB will continue oversight of active studies until closure or a mutually agreed-upon transfer of the studies.
- 2.4.5. Upon request or when required by law, the Carilion Clinic will execute an Authorization Agreement with the relying organization, which documents respective authorities, roles, responsibilities, and communication between this Carilion Clinic and the relying organization.
- 2.4.6. Investigators and research staff ultimately report to the Carilion Clinic Institutional Official for HRPP issues and are to follow the obligations described in "POLICY: Investigator Obligations (HRP-070)."
- 2.4.7. The [Chief Compliance Officer] works with the Carilion Clinical Institutional Official]on HRPP issues and is responsible to:
  - 2.4.7.1. Determine who is a <Legally Authorized Representative>, <Child>, and <Guardian>
  - 2.4.7.2. Provide legal advice related to the HRPP to the Carilion Clinical Institutional Official, IRB, and investigators
  - 2.4.7.3. Determine who is an agent for purposes of engagement
  - 2.4.7.4. Identify relevant state and international laws
  - 2.4.7.5. Resolve conflicts among applicable laws
- 2.4.8. Grants and Contracts Office works with the Carilion Clinical Institutional Official on HRPP issues.
  - 2.4.8.1. The Grants and Contracts Office is responsible to review contracts for compliance with HRPP requirements.
- 2.5. Written Procedures
  - 2.5.1. The Carilion Clinic makes written materials describing the HRPP available to all members of the Carilion Clinic through its Web site at https://www.carilionclinic.org/institutional-review-board.
  - 2.5.2. The Carilion Clinic makes written materials describing the HRPP available to sponsors, CROs, and investigators upon request when those materials apply to the requestor.
  - 2.5.3. When written materials are changed, the Carilion Clinic communicates to affected individuals through one or more of the following actions:
    - 2.5.3.1. Email communications
    - 2.5.3.2. Web-site postings
    - 2.5.3.3. Direct outreach at organizational meetings
    - 2.5.3.4. Training
    - 2.5.3.5. PRIS3M On-line IRB submission system
- 2.6. <Reliance Agreements>
  - 2.6.1. For federally funded research that must follow the <Revised Rule> (with the exception of exempt research for which IRB review is not required by regulation) that takes place at an institution in which IRB oversight is conducted by an IRB that is not operated by the institution, the institution and the organization operating the IRB must document the institution's reliance on the IRB for oversight of the



research and the responsibilities that each entity will undertake to ensure compliance with the requirements of this policy.

- 2.7. Questions, Concerns, and Feedback
  - 2.7.1. The Carilion Clinic solicits questions, concerns, and feedback by making the document "BROCHURE: Should I Take Part in Research (HRP-900)" available on its Web site and available to investigators to provide to the public.
  - 2.7.2. Individuals should address questions, suggestions, concerns, or complaints about the IRB or human research protection program; allegations of undue influence, <Allegations of Noncompliance> or <Findings of Noncompliance> orally or in writing to:

Carley Emerson, MS, CIP, CCRP Human Protections Administrator 2001 Crystal Springs Ave, Suite 202 Roanoke, VA 24014 540-981-8097 caemerson@carilionclinic.org

2.7.3. Individuals may also contact the Carilion Clinical Institutional Official at:

Daniel Harrington, M.D. Vice President for Academic Affairs Riverside 2 M124 Roanoke, VA 24014 540-526-2521 DPHarrington@carilionclinic.org


2.7.4. The Carilion Clinic takes steps to protect employees and agents who report in good faith from retaliation and harassment. Immediately reports such concerns to the Carilion Clinical Institutional Official.

### 3. **REFERENCES**

3.1. "Ethical Principles and Guidelines for the Protection of Human Subjects of Research," The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, April 18, 1979, (http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html)

### 4. APPROVAL AND REVISIONS

4.1. 1/18/19: IRB Director, Carley Emerson, originally created and approved



MMM

4.2. Table of Applicability of Regulatory and Policy Requirements by Category of Research

Cotogony of Dopporch	Research initially reviewed, de	Research initially reviewed, determined exempt, or waived:		
Category of Research	Before Jan 21, 2019	On or after Jan 21, 2019		
FDA regulated research that is NOT emergency use <sup>2</sup> , compassion use, or device research on anonymous tissue specimens <sup>3</sup>	<ul> <li>FDA regulations</li> <li><original rule=""></original></li> <li>Subparts B, C, D</li> </ul>	<ul> <li>FDA regulations</li> <li><original rule=""></original></li> <li>Subparts B, C, D</li> </ul>		
Emergency use, compassion use, and device research on anonymous tissue specimens <sup>4</sup>	FDA regulations	<ul> <li>FDA regulations</li> </ul>		
Research regulated by federal department or agency other than DOJ or CPSC	<ul> <li><original rule=""><sup>5</sup></original></li> <li>Subparts B, C, D</li> </ul>	<ul><li><revised rule=""></revised></li><li>Subparts B, C, D</li></ul>		
Research regulated by DOJ or CPSC	<ul><li><original rule=""></original></li><li>Subparts B, C, D</li></ul>	<ul><li><original rule=""></original></li><li>Subparts B, C, D</li></ul>		
Unregulated research <sup>6</sup>	<ul> <li><original rule=""><sup>7</sup></original></li> <li>Subparts B, C, D</li> </ul>	<ul><li><hybrid rule=""></hybrid></li><li>Subparts B, C, D</li></ul>		

<sup>&</sup>lt;sup>2</sup> This includes emergency use as defined in 21 CFR 56.102(d) and described in 21 CFR 50.23(a) and (b). This does not include waiver of consent for planned emergency research.

<sup>&</sup>lt;sup>3</sup> <Research Involving Human Subjects as Defined by FDA> that is also <Research Involving Human Subjects as Defined by HHS>

<sup>&</sup>lt;sup>4</sup> <Research Involving Human Subjects as Defined by FDA> that is NOT <Research Involving Human Subjects as Defined by HHS>

<sup>&</sup>lt;sup>5</sup> On or after January 21, 2019, sponsors can request that the research in this category initially reviewed, determined exempt, or waived before January 21, 2019 be re-reviewed under the <Revised Rule>

<sup>&</sup>lt;sup>6</sup> <Research Involving Human Subjects as Defined by HHS> that is NOT subject to regulation by either FDA or a federal department or agency

<sup>&</sup>lt;sup>7</sup> On or after January 21, 2019, sponsors can request that the research in this category initially reviewed, determined exempt, or waived before January 21, 2019 be re-reviewed under the <Hybrid Rule>



IC	Document No.:	Edition No.:	Effective Date:	Page:
oard	HRP-010	001	18 Jan 2019dd	Page 10 of 10
			MMMAXAAAA	

4.3. Table of Applicability of Regulatory and Policy Requirements by Requirement

Requirement	Research initially reviewed, d	etermined exempt, or waived:	
Requirement	Before Jan 21, 2019	On or after Jan 21, 2019	
FDA regulations	FDA regulated research	<ul> <li>FDA regulated research</li> </ul>	
<original rule=""></original>	<ul> <li>Research regulated by a federal department or agency</li> <li>FDA regulated research that is NOT emergency use, compassion use, or device research on anonymous tissue specimens</li> </ul>	<ul> <li>Research regulated by DOJ or CPSC</li> <li>FDA regulated research that is NOT emergency use, compassion use, or device research on anonymous tissue specimens</li> </ul>	
<revised rule=""></revised>	NA	<ul> <li>Research regulated by federal department or agency other than DOJ or CPSC</li> </ul>	
<hybrid rule=""></hybrid>	NA	<ul> <li>Unregulated research<sup>8</sup></li> </ul>	
Subparts B, C, D	<ul> <li>All research except, emergency use, compassion use, and device research on anonymous tissue specimens<sup>9</sup></li> </ul>	<ul> <li>All research except, emergency use, compassion use, and device research on anonymous tissue specimens</li> </ul>	

### 5. APPROVAL AND REVISIONS

5.1. 1/18/19: IRB Director, Carley Emerson, originally created and approved

<sup>&</sup>lt;sup>8</sup> <Research Involving Human Subjects as Defined by HHS> that is NOT subject to regulation by either FDA or a federal department or agency

<sup>&</sup>lt;sup>9</sup> <Research Involving Human Subjects as Defined by HHS> including FDA regulated research that is also <Research Involving Human Subjects as Defined by HHS>